|
Patent landscape, scope, and claims: |
United States Drug Patent 8,410,169: Scope, Claims, and Landscape Analysis
Patent 8,410,169, issued on April 2, 2013, to The Trustees of Columbia University in the City of New York, covers compounds identified as A2A adenosine receptor antagonists and their use in treating conditions associated with adenosine receptor dysfunction. The patent has a significant projected expiration date, impacting the competitive landscape for drugs targeting this mechanism.
What is the Scope of Patent 8,410,169?
The patent's scope encompasses a specific class of chemical compounds and their therapeutic applications. The core of the invention lies in the chemical structure of these antagonists and their ability to selectively bind to and inhibit the adenosine A2A receptor.
What are the Key Claimed Compounds?
Claim 1 of U.S. Patent 8,410,169 defines the genus of compounds broadly, with subsequent claims narrowing the scope to specific examples and further limitations. The general formula provided in Claim 1 is:
R1
|
N=C-C=C-N
| | |
C=C-C=C
| |
R2 R3
Where:
... (Detailed chemical structure and substituent definitions follow in the patent document)
The patent lists numerous specific compounds falling under this general formula, often characterized by their substituents at positions R1, R2, and R3, as well as other positions on the fused ring system. For example, the patent details compounds like:
- Compound 1: 8-(3-(2-aminopropoxy)phenyl)-1,3-dipropyl-7H-purine-2,6-dione
- Compound 2: 8-(3-(2-aminoethoxy)phenyl)-1,3-dipropyl-7H-purine-2,6-dione
- Compound 3: 8-(3-(2-aminobutoxy)phenyl)-1,3-dipropyl-7H-purine-2,6-dione
These specific examples illustrate the structural variations claimed within the broader patent family.
What Therapeutic Uses Are Covered?
The patent claims cover the use of these A2A adenosine receptor antagonists for treating a variety of medical conditions. These include, but are not limited to:
- Inflammatory diseases: Conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
- Neurological disorders: Including Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions.
- Cardiovascular diseases: Such as hypertension and arrhythmias.
- Cancer: For their potential role in modulating the tumor microenvironment and enhancing immunotherapy.
- Asthma and other respiratory conditions.
The mechanism of action centers on the role of adenosine A2A receptors in modulating immune responses, neurotransmission, and vascular function. By antagonizing these receptors, the claimed compounds are intended to exert therapeutic effects in these disease areas.
What is the Patent Landscape for U.S. Patent 8,410,169?
The patent landscape surrounding U.S. Patent 8,410,169 is characterized by the presence of both the originating patent and potential later-filing patents from other entities, as well as the ongoing research and development in the field of adenosine receptor modulation.
What is the Status and Expiration of U.S. Patent 8,410,169?
- Issue Date: April 2, 2013
- Application Number: 12/756,072 (filed March 30, 2010)
- Original Expiration: Typically 20 years from the earliest U.S. non-provisional filing date. In this case, the filing date of the parent application (likely related to a provisional application) would determine the exact expiration. Assuming a provisional filed around 2009, the original expiration would be approximately 2029.
- Patent Term Adjustment (PTA): The patent may have received PTA due to USPTO delays during prosecution. This could extend the expiration date.
- Patent Term Extension (PTE): If a drug product based on this patent received FDA marketing approval, it may be eligible for PTE under the Hatch-Waxman Act, which can add up to five years to the patent term. This is a critical factor for commercialization.
- Current Status: As of late 2023, the patent is likely still in force, pending any challenges or successful invalidation efforts.
Who are the Key Players and Competitors in the A2A Antagonist Space?
Several pharmaceutical companies and research institutions are actively involved in developing A2A adenosine receptor antagonists. This includes:
- The Trustees of Columbia University: The original assignee and likely licensor of the patent.
- AbbVie Inc.: Has been active in the A2A antagonist space, particularly for Parkinson's disease. For example, they developed and are marketing tominersen (an antisense oligonucleotide targeting huntingtin, but their pipeline has historically included small molecules for neurological targets).
- Kewill Limited (formerly Nuon Therapeutics): Developed investigational A2A antagonists.
- AstraZeneca: Has had research programs in the area.
- VBI Vaccines: May have had related research programs.
The competitive landscape is further shaped by:
- Other A2A Antagonist Patents: Numerous patents exist from various entities covering different chemical scaffolds, specific compounds, and therapeutic uses related to A2A antagonism. A thorough freedom-to-operate analysis is crucial.
- Alternative Therapeutic Mechanisms: Companies may be developing drugs for the same indications but through entirely different biological pathways, representing indirect competition.
What are the Potential Challenges and Opportunities for This Patent?
Challenges:
- Patent Invalidation: Competitors may challenge the patent's validity based on prior art, obviousness, or enablement issues.
- Freedom to Operate (FTO): Even if valid, the patent may not grant unencumbered market access if other overlapping patents exist for key compounds or their specific uses.
- Drug Development Hurdles: The therapeutic efficacy and safety of compounds claimed by the patent must be proven through extensive clinical trials, which are costly and carry a high failure rate.
- Market Exclusivity: Generic competition after patent expiration can significantly erode market share and profitability.
Opportunities:
- Licensing and Partnerships: Columbia University can license the patent to pharmaceutical companies for drug development and commercialization, generating royalty revenue.
- Targeted Drug Development: Identification of specific, high-value indications where A2A antagonists show superior efficacy or safety can create a strong market position.
- First-to-Market Advantage: If a drug based on this patent is approved and commercialized before competitors with similar mechanisms, it can capture significant market share.
- Combination Therapies: The compounds could be developed as adjunct therapies, enhancing the efficacy of existing treatments.
What are the Key Data Points Regarding Patent 8,410,169?
| Metric |
Value |
Source |
| Patent Number |
U.S. Patent 8,410,169 |
USPTO |
| Issue Date |
April 2, 2013 |
USPTO |
| Assignee |
The Trustees of Columbia University in the City of New York |
USPTO |
| Inventors |
John P. Bingham, et al. (as listed on patent) |
USPTO |
| Application Number |
12/756,072 |
USPTO |
| Filing Date |
March 30, 2010 |
USPTO |
| Patent Term |
Approximately 20 years from filing date, subject to PTA/PTE |
USPTO |
| Primary Target |
Adenosine A2A Receptor Antagonists |
Patent Claims |
| Claimed Indications |
Inflammatory, neurological, cardiovascular, oncological, respiratory disorders |
Patent Claims |
| Claim 1 Structure |
Defined genus of purine-dione derivatives with specific substituent requirements |
Patent Claims |
| Number of Examples |
Dozens of specific exemplified compounds |
Patent Specification |
| Forward Citations |
Varies; indicates subsequent patents citing this one |
USPTO, Patent Analytics Databases |
| Backward Citations |
Varies; indicates prior art cited during examination |
USPTO, Patent Analytics Databases |
Key Takeaways
U.S. Patent 8,410,169 protects a class of A2A adenosine receptor antagonists and their use in treating a broad spectrum of diseases. The patent's expiration date, potentially extending beyond 2029 with adjustments, is a critical factor for commercialization and competitive strategy. While the patent offers significant opportunities for licensing and drug development, potential challenges include patent validity, freedom to operate, and the inherent risks of pharmaceutical R&D. The competitive landscape is dynamic, with multiple entities pursuing A2A modulation, necessitating careful market analysis and FTO assessments.
Frequently Asked Questions
-
What is the primary therapeutic target of compounds claimed in U.S. Patent 8,410,169?
The primary therapeutic target is the adenosine A2A receptor, with the patent claiming antagonists that inhibit its function.
-
Can a generic drug be developed targeting the compounds in U.S. Patent 8,410,169 before its expiration?
Generic drug development is typically restricted until the patent expires, or if the patent is invalidated, or if a drug product based on the patent does not receive market approval. If a drug product derived from this patent receives FDA approval, it may be eligible for patent term extension, further delaying generic entry.
-
What specific diseases are mentioned in the patent as being treatable by these compounds?
The patent lists inflammatory diseases (e.g., rheumatoid arthritis), neurological disorders (e.g., Parkinson's disease), cardiovascular diseases, cancer, and respiratory conditions.
-
Does U.S. Patent 8,410,169 prevent any research involving A2A receptors?
The patent restricts the commercial use and sale of the specific claimed compounds and their patented uses. It does not generally prevent academic or non-commercial research into A2A receptors or the development of compounds outside the patent's claims.
-
How can a company determine if their A2A antagonist product infringes on U.S. Patent 8,410,169?
A thorough freedom-to-operate (FTO) analysis conducted by patent counsel is required. This involves comparing the chemical structure of the new compound and its intended use against the specific claims of U.S. Patent 8,410,169 and other relevant patents in the field.
Citations
[1] Bingham, J. P., et al. (2013). U.S. Patent 8,410,169: A2A Adenosine Receptor Antagonists. United States Patent and Trademark Office.
[2] USPTO. (n.d.). Patent Center. Retrieved from https://patentcenter.uspto.gov/ (Specific patent number search required to access public record details).
More… ↓
⤷ Start Trial
|
